Skip to main content

Analysing the ethics of breast cancer overdiagnosis: a pathogenic vulnerability

Medicine, Health Care and Philosophy volume 22, pages 129–140 (2019)Cite this article

Abstract

Breast cancer screening aims to help women by early identification and treatment of cancers that might otherwise be life-threatening. However, breast cancer screening also leads to the detection of some cancers that, if left undetected and untreated, would not have damaged the health of the women concerned. At the time of diagnosis, harmless cancers cannot be identified as non-threatening, therefore women are offered invasive breast cancer treatment. This phenomenon of identifying (and treating) non-harmful cancers is called overdiagnosis. Overdiagnosis is morally problematic as it leads to overall patient harm rather than benefit. Further, breast cancer screening is offered in a context that exaggerates cancer risk and screening benefit, minimises risk of harm and impedes informed choice. These factors combine to create pathogenic vulnerability. That is, breast cancer screening exacerbates rather than reduces women’s vulnerability and undermines women’s agency. This paper provides an original way of conceptualising agency-supporting responses to the harms of breast cancer overdiagnosis through application of the concept of pathogenic vulnerability.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Notes

  1. Scholars differ in formal definitions of overdiagnosis (see e.g., Hofmann 2014; Carter et al. 2016; Rogers and Mintzker 2016). However, all of these authors would include breast cancer overdiagnosis as described here within their definitions of overdiagnosis.

  2. Note that overdiagnoses differ from false positives which occur when an initial positive test is found to be incorrect on further testing.

  3. The rate of overdiagnosis may be expressed in relation to numbers of women invited to be screened, women actually screened, or cancers detected by screening. The number of overdiagnosed cancers may be presented as a percentage of the cancers diagnosed in the screening group or as the percentage of excess cancers found in screened women versus the numbers of cancers in unscreened women (Marmot 2012, p 41).

  4. I thank an anonymous reviewer for noting that all of these are iatrogenic harms. The harms of ODx are a subset of these.

  5. These incorrect beliefs about screening included:

    • screening prevents or reduces the risk of contracting breast cancer (68% believed this but screening has no effect on this risk);

    • screening at least halves breast cancer mortality (62% believed this but even the most optimistic estimates are a reduction of no more than 31% rather than 50% [Paci 2012]);

    • 10 years of regular screening will prevent 10 or more breast cancer deaths per 1000 women (75% of women believed this, whereas the real figure is thought to be between 0.3 and 3.2 per 1000 [Welch and Passow 2014]).

  6. These include methodological and contextual features that preclude meaningful comparisons of trials, ever-evolving diagnostic technologies, improvements in breast cancer treatment outcomes that change the baseline by reducing the anticipated benefit conferred by early diagnosis, and uncertainty about the most effective treatment for DCIS, which is detected almost exclusively through screening (Carter et al. 2015).

  7. This is not a carte blanche for any level of ODx: Australian women’s stated willingness to be screened is sensitive to potential rates of overdiagnosis. Rates of up to 30% ODx had little impact on intentions and attitudes to screening. Rates of 50% prompted some women to decline screening altogether although others retained an unchanged commitment to participate (Hersch et al. 2013).

  8. The percentages rose to 50 and 19% respectively regarding ‘conceptual information’ only (i.e., general understanding of the issues rather than recall of specific numerical information).

  9. These authors defined informed choice in terms of adequate knowledge about the benefits and harms of screening including overdiagnosis and intentions consistent with attitudes.

  10. I am indebted to my colleagues Stacy Carter, Bjorn Hofmann and Lynette Reid for this term, ‘epistemic burden’.

  11. The Swiss Medical Board is notable here for shouldering the epistemic burden. After 12 months of deliberation, the Board decided to time limit existing screening mammography programs and not introduce any new ones (Biller-Andorno and Jüni 2014).

  12. For example, screening for cervical cancer is generally accepted to have made a major contribution to the decrease in deaths from this disease, although this belief has never been tested in a randomized controlled trial.

References

  • Agrawal, Sushma. 2014. Late effects of cancer treatment in breast cancer survivors. South Asian Journal of Cancer 3 (2): 112–115.

    Article  Google Scholar 

  • American Cancer Society. 2011. Cancer facts & figures. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2011/cancer-facts-and-figures-2011.pdf. Accessed Dec 4 2017.

  • Ban, Kristen A., and Constantine V. Godellas. 2014. Epidemiology of breast cancer. Surgical Oncology Clinics of North America 23 (3): 409–422.

    Article  Google Scholar 

  • Barratt, Alexandra. 2015. Overdiagnosis in mammography screening: A 45 year journey from shadowy idea to acknowledged reality. BMJ: British Medical Journal. 350: h867. https://doi.org/10.1136/bmj.h867.

  • Bayer, Ron, and Amy L. Fairchild. 2016. Means, ends and the ethics of fear-based public health campaigns. Journal of Medical Ethics 42: 391–396.

    Article  Google Scholar 

  • Beckjord, Ellen B., Kerry A. Reynolds, G.J. van Londen, Rachel Burns, Reema Singh, Sarah R. Arvey, Stephanie A. Nutt, and Ruth Rechis. 2014. Population-level trends in posttreatment cancer survivors’ concerns and associated receipt of care: Results from the 2006 and 2010 LIVESTRONG surveys. Journal of Psychosocial Oncology 32 (2): 125–151.

    Article  Google Scholar 

  • Biller-Andorno, Nicola and Peter Jüni. 2014. Abolishing mammography screening programs? A view from the Swiss Medical Board. New England Journal of Medicine 370 (21): 1965–1967.

    Article  Google Scholar 

  • Blinder, Victoria, Carolyn Eberle, Sujata Patil, Francesca M. Gany, and Cathy J. Bradley. 2017. Women with breast cancer who work for accommodating employers more likely to retain jobs after treatment. Health Affairs 36 (2): 274–281.

    Article  Google Scholar 

  • Boyages, John, Senia Kalfa, Ying Xu, Louise Koelmeyer, Helen Mackie, Hector Viveros, Lucy Taksa, and Paul Gollan. 2016. Worse and worse off: The impact of lymphedema on work and career after breast cancer. SpringerPlus 5 (1): 657–664.

    Article  Google Scholar 

  • Breastscreen NSW. 2017. Cancer Institute New South Wales. https://www.breastscreen.nsw.gov.au/. Accessed Dec 4 2017.

  • Brennan, Meagan, and Nehmat Houssami. 2016. Discussing the benefits and harms of screening mammography. Maturitas 92: 150–153.

    Article  Google Scholar 

  • Carter, Stacy M., Jane Williams, Lucy Parker, Kristen Pickles, Gemma Jacklyn, Lucy Rychetnik and Alexandra Barratt. 2015. Screening for cervical, prostate, and breast cancer: Interpreting the evidence. American Journal of Preventive Medicine 49 (2): 274–285.

    Article  Google Scholar 

  • Carter, Stacy M., Christopher Degeling, Jennifer Doust, and Alexandra Barratt. 2016. A definition and ethical evaluation of overdiagnosis. Journal of Medical Ethics 42 (11): 705–714.

    Article  Google Scholar 

  • Clarke, Juanne N., and Michelle M. Everest. 2006. Cancer in the mass print media: Fear, uncertainty and the medical model. Social Science & Medicine 62 (10): 2591–2600.

    Article  Google Scholar 

  • Dartois, Laureen, Guy Fagherazzi, Laura Baglietto, Marie-Christine Boutron-Ruault, Suzette Delaloge, Sylvie Mesrine, and Francoise Clavel-Chapelon. 2016. Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the E3N-EPIC cohort. International Journal of Cancer 138 (10): 2415–2427.

    Article  Google Scholar 

  • Domenighetti, Gianfranco, Barbara D’Avanzo, Matthias Egger, Franco Berrino, Thomas Perneger, Paolo Mosconi and Marcel Zwahlen. 2003. Women’s perception of the benefits of mammography screening: Population-based survey in four countries. International Journal of Epidemiology 32 (5): 816–821.

    Article  Google Scholar 

  • Drageset, Sigrunn, Torill Christine Lindstrøm, and Kjell Underlid. 2016. “I just have to move on”: Women’s coping experiences and reflections following their first year after primary breast cancer surgery. European Journal of Oncology Nursing 21: 205–211.

    Article  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group. 2015. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. The Lancet 386 (10001): 1341–1352.

    Article  Google Scholar 

  • Elmore, Joann G. 2016. Solving the problem of overdiagnosis. The New England Journal of Medicine 375 (15): 1483–1486.

    Article  Google Scholar 

  • Entwistle, Vikki, Stacy M. Carter, Lyndall Trevena, Kathy Flitcroft, Les Irwig, Kirsten McCaffery and Glen Salkeld. 2008. Communicating about screening. British Medical Journal 337:a1591.

    Article  Google Scholar 

  • Gernaat, S., P. Ho, N. Rijnberg, M. Emaus, L. Baak, M. Hartman, D. Grobbee, and H. Verkooijen. 2017. Risk of death from cardiovascular disease following breast cancer: A systematic review. Breast Cancer Research and Treatment 164 (3): 537–555.

    Article  Google Scholar 

  • Ghanouni, Alex, Susanne F. Meisel, Jolyn Hersch, Jo Waller, Jane Wardle and Cristina Renzi. 2016. Information on’overdiagnosis’ in breast cancer screening on prominent United Kingdom-and Australia-oriented health websites. PLoS ONE 11 (3): e0152279.

    Article  Google Scholar 

  • Gigerenzer, Gerd. 2015. Towards a paradigm shift in cancer screening: Informed citizens instead of greater participation. BMJ: British Medical Journal 350: h2175.

    Article  Google Scholar 

  • Hersch, Jolyn, Jesse Jansen, Les Irwig, Alexandra Barratt, Hazel Thornton, Kirsten Howard, and Kirsten McCaffery. 2011. How do we achieve informed choice for women considering breast screening? Preventive Medicine 53 (3): 144–146.

    Article  Google Scholar 

  • Hersch, Jolyn, Jesse Jansen, Alexandra Barratt, Les Irwig, Nehmat Houssami, Kirsten Howard, Haryana Dhillon and Kirsten McCaffery. 2013. Women’s views on overdiagnosis in breast cancer screening: A qualitative study. British Medical Journal 346:f158.

    Article  Google Scholar 

  • Hersch, Jolyn, Alexandra Barratt, Jesse Jansen, Les Irwig, K. McGeechan, Gemma Jacklyn, Hazel Thornton, Haryana Dhillon, Nehmat Houssami and Kirsten McCaffery. 2015. Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: A randomised controlled trial. The Lancet 385 (9978): 1642–1652.

    Article  Google Scholar 

  • Hofmann, Bjorn. 2014. Diagnosing overdiagnosis: Conceptual challenges and suggested solutions. European Journal of Epidemiology 28: 599–604.

    Article  Google Scholar 

  • Howson, Alexandra. 1998. Embodied obligation: The female body and health surveillance. In The body in everyday life, eds. S. Nettleton, and J. Watson, 218–241. London: Routledge.

    Google Scholar 

  • Jørgensen, Karsten J., Mette Kalager, Alexandra Barratt, Cornelia Baines, Per-Henrik Zahl, John Brodersen, and Russell P. Harris. 2017. Overview of guidelines on breast screening: Why recommendations differ and what to do about it. The Breast 31: 261–269.

    Article  Google Scholar 

  • Keen, John D., and Karsten J. Jørgensen. 2015. Four principles to consider before advising women on screening mammography. Journal of Women’s Health 24 (11): 867–874.

    Article  Google Scholar 

  • Kummerow, Kristy L., Liping Du, David F. Penson, Yu Shyr, and Mary A. Hooks. 2015. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surgery 150 (1): 9–16.

    Article  Google Scholar 

  • Lindberg, Laura G., Mette Svendsen, Mikala Dømgaard, and John Brodersen. 2013. Better safe than sorry: A long-term perspective on experiences with a false-positive screening mammography in Denmark. Health, Risk & Society 15 (8): 699–716.

    Article  Google Scholar 

  • Lupton, Deborah. 1995. The imperative of health: Public health and the regulated body. vol. 90. London: Sage Publications.

    Google Scholar 

  • Mackenzie, Catriona, Wendy Rogers and Susan Dodds. 2014. Vulnerability: New essays in ethics and feminist philosophy. Oxford: Oxford University Press.

    Google Scholar 

  • Marmot, Michael G. 2012. The benefits and harms of breast cancer screening: An independent review. The Lancet 380 (9855): 1778–1786.

    Article  Google Scholar 

  • Mehnert, Anja. 2011. Employment and work-related issues in cancer survivors. Critical Reviews in Oncology/Hematology 77 (2): 109–130.

    Article  Google Scholar 

  • Myers, Evan R., Patricia Moorman, Jennifer M. Gierisch, Laura J. Havrilesky, Lars J. Grimm, Sujata Ghate, Brittany Davidson, Ranee C. Mongtomery, Matthew J. Crowley, Douglas C. McCrory, Amy Kendrick and Gillian Sanders. 2015. Benefits and harms of breast cancer screening: A systematic review. Journal of the American Medical Association 314 (15): 1615–1634.

    Article  Google Scholar 

  • Nelson, Heidi D., Rochelle Fu, Amy Cantor, Miranda Pappas, Monica Daeges, and Linda Humphrey. 2016. Effectiveness of breast cancer screening: Systematic review and meta-analysis to update the 2009 US preventive services task force recommendation effectiveness of breast cancer screening. Annals of Internal Medicine 164 (4): 244–255.

    Article  Google Scholar 

  • NHMRC. 2007. National Statement on Ethical Conduct in Human Research 2007 (Updated May 2015). National Health and Medical Research Council, Australian Research Council and Australian Vice-Chancellors’ Committee Canberra, ACT.

  • Nomura, Sarah J., Maki Inoue-Choi, DeAnn Lazovich and Kim Robien. 2016. WCRF/AICR recommendation adherence and breast cancer incidence among postmenopausal women with and without non-modifiable risk factors. International Journal of Cancer 138 (11): 2602–2615.

    Article  Google Scholar 

  • Ozakinci, Gozde, Aleksandra Sobota, and Gerry Humphris. 2014. Fear of cancer recurrence among breast cancer survivors. Current Breast Cancer Reports 6 (3): 219–225.

    Article  Google Scholar 

  • Paci, Eugenio. 2012. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. Journal of Medical Screening 19 (Suppl 1): 5–13.

    Article  Google Scholar 

  • Parker, Lisa M., and Stacy M. Carter. 2016. The role of socially embedded concepts in breast cancer screening: An empirical study with Australian experts. Public Health Ethics 9 (3): 276–289.

    Article  Google Scholar 

  • Parker, Lisa M., Lucy Rychetnik, and Stacy M. Carter. 2015. The role of communication in breast cancer screening: A qualitative study with Australian experts. BMC Cancer 15 (1): 741.

    Article  Google Scholar 

  • Ploug, Thomas, Soren Holm, and John Brodersen. 2012. To nudge or not to nudge: Cancer screening programmes and the limits of libertarian paternalism. Journal of Epidemiology and Community Health 66: 1193–1196.

    Article  Google Scholar 

  • Quanstrum, Kerrianne H., and Rodney A. Hayward. 2010. Lessons from the mammography wars. The New England Journal of Medicine 363 (11): 1076–1079.

    Article  Google Scholar 

  • Rogers, Wendy A., and Yishai Mintzker. 2016. Getting clearer on overdiagnosis. Journal of Evaluation in Clinical Practice 22: 580–587.

    Article  Google Scholar 

  • Rogers, Wendy, Catriona Mackenzie and Susan Dodds. 2012. Why bioethics needs a concept of vulnerability. International Journal of Feminist Approaches to Bioethics 5 (2): 11–38.

    Article  Google Scholar 

  • Rogers, Wendy, Wendy Craig, and Vikki Entwistle. 2017. Ethical issue raised by thyroid cancer overdiagnosis: A matter of public health? Bioethics 31 (8): 590–598.

    Article  Google Scholar 

  • Schwartz, Lisa M., Steven Woloshin, Floyd J Fowler Jr., and H. Gilbert Welch. 2004. Enthusiasm for cancer screening in the United States. Journal of the American Medical Association 291 (1): 71–78.

    Article  Google Scholar 

  • Silverman, E., Steven Woloshin, Lisa Schwartz, S. Byram, H. Gilbert Welch, and B. Fischhoff. 2001. Women’s views on breast cancer risk and screening mammography: A qualitative interview study. Medical Decision Making 21 (3): 231–240.

    Article  Google Scholar 

  • Sisti, Julia S., Laura C. Collins, Andrew H. Beck, Rulla M. Tamimi, Bernard A. Rosner and A. Heather Eliassen. 2016. Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses’ health studies. International Journal of Cancer 138 (10): 2346–2356.

    Article  Google Scholar 

  • Sun, Yuanlu, Cheryl L. Shigaki, and Jane M. Armer. 2017. Return to work among breast cancer survivors: A literature review. Supportive Care in Cancer 25 (3): 709–718.

    Article  Google Scholar 

  • van Agt Heleen, Jacques Fracheboud, Annemieke van der Steen and Harry de Koning. 2012. Do women make an informed choice about participating in breast cancer screening? A survey among women invited for a first mammography screening examination. Patient Education and Counseling 89 (2): 353–359.

    Article  Google Scholar 

  • Vickberg, Suzanne M. J. 2003. The Concerns About Recurrence Scale (CARS): A systematic measure of women’s fears about the possibility of breast cancer recurrence. Annals of Behavioral Medicine 25 (1): 16–24.

    Article  Google Scholar 

  • Walker, Mary J., and Wendy A. Rogers. 2017a. Reasonableness, credibility, and clinical disagreement. AMA Journal of Ethics 19 (2): 176–182.

    Article  Google Scholar 

  • Walker, Mary J., and Wendy A. Rogers. 2017b. Diagnosis, identity, and the experience of asymptomatic disease. Theoretical Medicine and Bioethics 38 (4): 307–321.

    Article  Google Scholar 

  • Waller, Jo, Katy Osborne, and Jane Wardle. 2015. Enthusiasm for cancer screening in Great Britain: A general population survey. British Journal of Cancer 112 (3): 562–566.

    Article  Google Scholar 

  • Wegwarth, Odette, and Gerd Gigerenzer. 2013. Overdiagnosis and overtreatment: Evaluation of what physicians tell their patients about screening harms. JAMA Internal Medicine 173 (22): 2086–2088.

    Article  Google Scholar 

  • Welch, H. Gilbert, and Honor J. Passow. 2014. Quantifying the benefits and harms of screening mammography. JAMA Internal Medicine 174 (3): 448–454.

    Article  Google Scholar 

  • Welch, H. Gilbert, Lisa M. Schwartz and Steven Woloshin. 2011. Overdiagnosed: Making people sick in the pursuit of health. Boston: Beacon Press.

    Google Scholar 

  • Welch, H., Philip C. Gilbert, A. Prorok, James, O’Malley, and Barnett S. Kramer. 2016. Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. New England Journal of Medicine 375 (15): 1438–1447.

    Article  Google Scholar 

  • Willis, Karen. 2004. Personal choice/social responsibility: Women aged 40–49 years and mammography screening. Journal of Sociology 40 (2): 121–136.

    Article  Google Scholar 

  • World Health Organization. 2013. Women’s health. Geneva: World Health Organization. http://www.portal.pmnch.org/mediacentre/factsheets/fs334/en/. Accessed Dec 4 2017.

  • Yin, Wesley, Ruslan Horblyuk, Julia J. Perkins, Steve Sison, Greg Smith, Julia T. Snider, Yanyu Wu, and Tomas J. Philipson. 2017. Association between breast cancer disease progression and workplace productivity in the United States. Journal of Occupational and Environmental Medicine 59 (2): 198–204.

    Article  Google Scholar 

Download references

Acknowledgements

Work on this paper was funded by Australian Research Council FT130100346, awarded to Professor Wendy Rogers. An earlier version was presented as part of a panel at the 2016 Feminist Approaches to Bioethics World Congress in Edinburgh. Thanks to my co-panellists Stacy Carter and Lynette Reid, members of the audience, and also to Mary Walker for helpful comments on earlier drafts.

Author information

Authors and Affiliations

  1. Department of Philosophy and Department of Clinical Medicine, Macquarie University, North Ryde, NSW, 2107, Australia

    Wendy A. Rogers

Authors
  1. Wendy A. Rogers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wendy A. Rogers.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rogers, W.A. Analysing the ethics of breast cancer overdiagnosis: a pathogenic vulnerability. Med Health Care and Philos 22, 129–140 (2019). https://doi.org/10.1007/s11019-018-9852-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11019-018-9852-z

Keywords

  • Overdiagnosis
  • Breast cancer
  • Vulnerability
  • Screening
  • Harm
  • Pathogenic vulnerability
  • Ethics